<DOC>
	<DOCNO>NCT00075946</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody rituximab locate cancer cell either kill deliver cancer-killing substance without harm normal cell . It yet know rituximab regimen effective treat indolent non-Hodgkin 's lymphoma . PURPOSE : This randomized phase III trial study two different schedule rituximab compare see well work treat patient low tumor burden indolent stage III non-Hodgkin 's lymphoma stage IV non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Rituximab Treating Patients With Low Tumor Burden Indolent Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - To compare time rituximab failure rituximab schedule rituximab retreatment arm . Secondary - To compare time first cytotoxic therapy rituximab schedule rituximab retreatment arm . - To document rationale begin cytotoxic therapy ; define chemotherapy , radiation therapy radioimmunotherapy . - To compare toxicity associate rituximab therapy two randomized treatment arm . - Quality Life Objectives : 1 . To compare health-related quality life , distress , psychological functioning , physical well-being functional well-being patient receive rituximab schedule receive rituximab retreatment . 2 . To examine impact differential treatment response ( delayed time rituximab failure and/or time first cytotoxic therapy ) , observe , quality life , distress , psychological functioning patient receive rituximab schedule receive rituximab retreatment . 3 . To obtain prospective data physical functional well-being treatment rituximab . OUTLINE : This randomize , multicenter study . Patients stratify accord histologic subtype ( follicular v ) , age ( 60 vs 60 ) , time diagnosis ( less 1 year v least 1 year ) . - Induction rituximab : Patients receive rituximab Intravenous ( IV ) week 4 week . Patients re-evaluated 9 week completion induction rituximab . Patients partial complete response induction rituximab randomize 1 2 treatment arm . - Arm A ( retreatment rituximab ) : Patients receive rituximab IV week 4 week upon disease progression provide time progression 6 month . - Arm B ( schedule rituximab ) : Patients receive single dose rituximab IV every 13 week disease progression absence unacceptable toxicity . Quality life assess induction rituximab treatment 26 , 39 , 65 , 117 , 169 , 221 week randomization . Patients follow least annually 15 year study entry .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>INCLUSION CRITERIA : Histologically confirm nonHodgkin 's lymphoma , include 1 following : Follicular grade 1 2 Small lymphocytic Marginal zone ( nodal ) Marginal zone ( splenic ) Mucosaassociated lymphoid tissue ( MALT ) Stage III IV disease Must meet follow criterion low tumor burden : No nodal extranodal mass least 7 cm Less 3 nodal mass great 3 cm diameter No systemic symptom B symptoms No splenomegaly great 16 cm compute tomography ( CT ) scan No evidence risk compression vital organ ( i.e. , ureteral epidural ) No leukemic phase great 5,000/mm^3 circulate lymphocyte No cytopenia , define follow : Platelet count le 100,000/mm^3 Hemoglobin less 10 g/dL Absolute neutrophil count le 1,500/mm^3 At least 1 objective measurable disease parameter Abnormal positron emission tomography ( PET ) scan constitute evaluable disease unless verify CT scan appropriate image Age : 18 Eastern Cooperative Oncology Group ( ECOG ) performance status 01 Must meet follow criterion lab : Hematopoietic Absolute neutrophil count least 1,500/mm^3* Hemoglobin least 10 g/dL* Platelet count least 100,000/mm^3* NOTE : *Without growth factor and/or transfusion support Hepatic Bilirubin great 2 time upper limit normal ( ULN ) OR direct bilirubin normal patient Gilbert 's Syndrome The aspartate transaminase ( AST ) alanine transaminase ( ALT ) ratio ( AST/ALT ) great 5 time ULN Hepatitis B surface antigen negative Renal Creatinine great 2 time ULN EXCLUSION CRITERIA : Evidence transformation large cell histology Pregnant nursing . Fertile patient must use effective contraception HIV positive Uncontrolled active infection Other malignancy within past 2 year except adequately treat basal cell squamous cell skin cancer carcinoma situ cervix Prior immunotherapy lymphoma Prior chemotherapy lymphoma Concurrent chemotherapy Prior radiotherapy lymphoma Concurrent radiotherapy Concurrent radioimmunotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage III small lymphocytic lymphoma</keyword>
	<keyword>stage III marginal zone lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
</DOC>